“Retatrutide is being submitted to FDA, so it will be available in 2027.”

Misleading

This statement leaves out a limit that changes its meaning.

Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.

What this answer is based on

This answer uses an official regulator record or a specific product label.

Limits of this answer

The sponsor-stated first-quarter 2027 U.S. submission plan as reviewed August 1, 2026. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.

Topic

Whether a specific product has an approval or another official status.